FORM 8-K/A
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 1998
MEDTOX SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-11394 95-3863205
(Commission File Number) (IRS Employer Identification No.)
402 West County Road D
St. Paul, Minnesota 55112
(Address of principal executive offices) (Zip Code)
(612) 636-7466
(Registrant's telephone number, including area code)
<PAGE>
Item 4. Change In Independent Accountants
Effective May 27, 1998, the Registrant terminated Ernst & Young LLP as its
independent accounting firm. The termination of Ernst & Young LLP was approved
by the Audit Committee of the Board of Directors of the Registrant.
Ernst & Young LLP's report on the financial statements of the Registrant for
each of the last two fiscal years neither contained an adverse opinion or a
disclaimer of opinion, nor was qualified or modified as to uncertainty, audit
scope, or accounting principles.
During the Registrant's two most recent fiscal years and the interim period
through May 27, 1998, there were no disagreements or "reportable events" with
Ernst & Young LLP as described in Items 304(a)(1)(iv) and (v) of Regulation S-K.
Accordingly, Ernst & Young LLP has not advised the Registrant of (i) the
absence of the internal controls necessary for the Registrant to develop
reliable financial statements, (ii) any information which would cause Ernst &
Young LLP to no longer rely on management's representations, or that Ernst &
Young LLP was unwilling to be associated with the financial statements prepared
by management, (iii) any need to expand significantly the scope of its audit, or
any information that if further investigated may (a) materially impact the
fairness or reliability of either a previously issued audit report or the
underlying financial statements or any financial statements for any fiscal
period subsequent to the date of the most recent financial statements covered by
an audit report or (b) cause it to be unwilling to rely on management's
representations or be associated with the Registrant's financial statements, or
(iv) any information that has come to the attention of Ernst & Young LLP that it
concluded materially impacts the fairness or reliability of either (a) a
previously issued audit report or the underlying financial statements or (b) any
financial statements issued or to be issued covering any fiscal period
subsequent to the date of the most recent financial statements covered by an
audit report.
Effective June 3, 1998, the Registrant engaged Deloitte & Touche LLP as its
independent accounting firm. Neither the Registrant or any of its subsidiaries
has had any prior relationships with Deloitte & Touche LLP.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDTOX Scientific, Inc.
Date: June 16, 1998 By: /s/ Peter J. Heath
--------------------
Name: Peter J. Heath
Title: Vice President of Finance
and Chief Financial Officer
<PAGE>
